Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 5/20 | 0.36 |
| ▸ | CA1 | P00915 | 5/20 | 0.36 |
| ▸ | CA2 | P00918 | 5/20 | 0.36 |
| ▸ | CA9 | Q16790 | 5/20 | 0.36 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | ESR1 | P03372 | 1/20 | 0.30 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.30 |
| ▸ | KDR | P35968 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8274028 | 0.84 | ALDH1A1 (0.39) | ALDH1A1HPGDCA12CA1CA2 | |
| SCHEMBL30017898 | 0.83 | HPGD (0.36) | ALDH1A1HPGDCA12CA1CA2 | |
| SCHEMBL7434676 | 0.81 | — | — | |
| SCHEMBL7434671 | 0.79 | — | — | |
| SCHEMBL9790658 | 0.77 | ALDH1A1 (0.38) | ALDH1A1HPGDCA12CA1CA2 | |
| SCHEMBL3588443 | 0.77 | ALDH1A1 (0.50) | ALDH1A1CA12CA1CA2CA9 | |
| SCHEMBL11230267 | 0.75 | ALDH1A1 (0.36) | ALDH1A1HPGDCA12CA1CA2 | |
| SCHEMBL21712508 | 0.75 | ALDH1A1 (0.36) | ALDH1A1HPGDCA12CA1CA2 | |
| SCHEMBL28579901 | 0.74 | ALDH1A1 (0.35) | ALDH1A1HPGDCA12CA1CA2 | |
| SCHEMBL31694271 | 0.74 | HPGD (0.32) | HPGDCA12CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070142435-A1 | [4-(5-Aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-(4-bromo-3-methyl-5-propoxy-thiophen-2-yl)-methanone hydrochloride as an inhibitor of mast cell tryptase | AVENTIS PHARMACEUTICALS INC. (US) | 2007-06-21 | — | — | US | disclosed |
| CN-1956978-A | [ 4- (5-aminomethyl-2-fluoro-phenyl) -piperidin-1-yl ] - (4-bromo-3-methyl-5-propoxy-thiophen-2-yl) -methanone hydrochloride as mast cell tryptase inhibitor | AVENTIS PHARMA INC (US) | 2007-05-02 | — | — | CN | disclosed |
| EP-1737848-A1 | [4-(5-AMINOMETHYL-2-FLUORO-PHENYL)-PIPERIDIN-1-YL]-(4-BROMO-3-METHYL-5-PROPOXY-THIOPHEN-2-YL)-METHANONE HYDROCHLORIDE AS AN INHIBITOR OF MAST CELL TRYPTASE | Aventis Pharmaceuticals Inc. (US) | 2007-01-03 | — | — | EP | disclosed |
| WO-2005097780-A1 | [4-(5-AMINOMETHYL-2-FLUORO-PHENYL)-PIPERIDIN-1-YL]-(4-BROMO-3-METHYL-5-PROPOXY-THIOPHEN-2-YL)-METHANONE HYDROCHLORIDE AS AN INHIBITOR OF MAST CELL TRYPTASE | AVENTIS PHARMACEUTICALS INC. (US) | 2005-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142435-A1 | [4-(5-Aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-(4-bromo-3-methyl-5-propoxy-thiophen-2-yl)-methanone hydrochloride as an inhibitor of mast cell tryptase | CMA1, TPSAB1, TPSB2 | ALDH1A1 355/4885HPGD 635/4885CA12 3440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.